Approval · Notice of Compliance 2369 · 2001
LYMERIX: Notice of Compliance 2369
Issued August 31, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2369
- Date
- August 31, 2001
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Two alternative dosing schedules and a serologic correlate of protection
- Therapeutic class
- Active immunizing agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LYMERIX | Not yet assigned | — |
Medicinal ingredients
- LIPOPROTEIN OSPA 30 MCG per 0.5ML